Trump Announces Potential Price Drop for Ozempic, Wegovy
President Donald Trump stated today that the price of Novo Nordisk’s weight-loss drug, Ozempic and its sister drug Wegovy, will be lowered, with negotiations expected to move quickly.
The announcement came during a White House event focused on fertility treatments and drug pricing, where reporters questioned Trump about a previously mentioned drug price reduction. “I was referring to Ozempic, or – I was referring to – the fat loss drug?… They’ll be much lower,” Trump said. Novo Nordisk markets Ozempic for diabetes management and Wegovy specifically for weight loss, both utilizing the same active ingredient, semaglutide. The rising cost of these medications has created access challenges for many Americans seeking treatment for obesity and related health conditions.
Trump indicated the price could be reduced to $150 from a current list price of approximately $1,000 per month, though Novo Nordisk directly sells to cash-pay customers for $499 monthly. A Novo Nordisk spokesperson confirmed discussions with the administration regarding the Most Favored Nation executive order, stating the company remains focused on improving patient access and affordability.
Dr. Mehmet Oz, administrator of the Centers for Medicare and Medicaid Services, clarified that price negotiations for GLP-1 drugs – the class Ozempic belongs to – are still ongoing. You can learn more about CMS efforts to lower drug costs on their website.
Officials stated that further details regarding the price reduction and negotiation timeline will be released as they become available.
